Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Otago researchers in major new study of TB and diabetes

Otago researchers in major new study of TB and diabetes epidemics

University of Otago expertise is set to play a key role in European Commission (EC) funded research into links between infectious and non-communicable diseases – in this case tuberculosis (TB) and type 2 diabetes.

The EC has earmarked €6 billion for health research under its Seventh Framework Programme (FP7) for the funding of research and technological development, of which €6 million (NZ$9.5 million) has been awarded to the new project.

Co-Director of the University’s Centre for International Health, Professor Philip Hill, says the initial call was for projects that combine one of the three major poverty-related diseases – HIV/AIDS, malaria and tuberculosis – with the major non-infectious diseases including rheumatic or cardiovascular disease, cancer and diabetes.

“This year nine million people will be diagnosed with TB and up to 1.4 million will die from it. We also know that just under 400 million people live with diabetes and around 10 - 20% of new cases of TB are also diabetic, which is a much higher percentage than you would expect by chance,” Professor Hill says.

“There are more TB cases with diabetes than there are with HIV and while diabetes doesn't have as dramatic an effect on TB as HIV does, it is clearly a significant player - presumably through an effect on the immune system. The fact that the number of people worldwide with diabetes is increasing at an alarming rate will have an effect on global TB control.”

Professor Hill, who has an extensive record in TB research in developing countries, will be part of a multi-disciplinary consortium linking field sites in four TB-endemic countries that are experiencing a rapid growth of type 2 diabetes – namely Romania, Peru, South Africa and Indonesia.

The €6 million (NZ$9.5 million) project, which will be known as TANDEM (Tuberculosis and Diabetes ­Mellitus), will see Otago researchers collaborating with leading laboratories in Germany, UK, Netherlands and Romania. The project’s official start date is 1 February 2013.

The consortium’s aim is to increase knowledge of the causative links between the two diseases and by doing that develop better prevention, treatment and management of them so that mortality rates can be reduced and quality of life improved.

Professor Hill, who was part of the team that designed the study, says the consortium wants to test the hypothesis that screening and management can be greatly improved and simplified with a major impact on the control of TB and diabetes co-morbidity.

“We will explore how best to screen people with TB for diabetes and we will also be able to give an indication, across continents, of the actual proportion of TB patients who also have diabetes, and their basic characteristics.”

TANDEM will also examine the best medications and treatments for TB in this group of patients and explore what their long-term requirements are in terms of diabetes treatment once they have finished their TB treatment.

The study will also look at the effect of glucose control on TB treatment outcome and also look for immune system abnormalities and genetic variations common to both diseases.

Professor Hill says one of the great plusses of a multi-site study like this is the greater statistical power it provides. The researchers will end up with 1500 - 2000 TB cases to study and of those, around 350-400 will also have diabetes.

Otago will be particularly involved in the study based in Indonesia, as part of their formal collaboration with Padjadjaran University, and that study alone will provide about 400 TB cases.

“It is a great privilege to be involved in a European Union study,” says Professor Hill.

“We couldn’t apply on our own; we needed to be part of a consortium and offer something that is not easily available within the EU. Our previous field studies in TB and our growing collaboration with Padjadjaran University provides that.”

ends

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Royal Society: Review Finds Community Water Fluoridation Safe And Effective

A review of the scientific evidence for and against the efficacy and safety of fluoridation of public water supplies has found that the levels of fluoridation used in New Zealand create no health risks and provide protection against tooth decay. More>>

ALSO:

Scoop Business: Croxley Calls Time On NZ Production In Face Of Cheap Imports

Croxley Stationery, whose stationery brands include Olympic, Warwick and Collins, plans to cease manufacturing in New Zealand because it has struggled to compete with lower-cost imports in a market where the printed word is giving way to electronic communications. More>>

ALSO:

Prefu Roundup: Forecasts Revised, Surplus Intact

The National government heads into the election with its Budget surplus target broadly intact, delivering a set of economic and fiscal forecasts marginally revised from May to reflect weaker commodity prices and a lower tax take. More>>

ALSO:

Convention Centre: Major New SkyCity Hotel And Laneway For Auckland

Today SKYCITY Entertainment Group Limited revealed plans to build a new hotel and pedestrian laneway of bars, restaurants and boutique shopping on land it owns in the Nelson and Hobson Streets block, expanding the SKYCITY Entertainment Precinct. More>>

ALSO:

Igniting The Spark: Bringing The Digital Enabler To Life

Changing a name is, relatively speaking, the easy part of a re-invention. Changing a culture, getting all the ducks in a row, turning yourself inside-out to become customer-inspired is a much bigger challenge. More>>

ALSO:

Ebola And NZ: Targeted Screening At Airport But Risk Low

The risk of any cases of Ebola in New Zealand remains very low, but health and border authorities are well prepared... anyone arriving in New Zealand who in the last three weeks has visited countries affected will be screened for symptoms of the disease. More>>

ALSO:

Scoop Business: Brewer Seeking Crowd-Funding Cancels Shareholders’ Dividends

Shareholders in Renaissance Brewing company, the first business to seek equity through crowd-funding in New Zealand, have cancelled their claim on $147,000 of accumulated earnings “to make Renaissance a more attractive investment opportunity.” More>>

ALSO:

Get More From Scoop

 
 
Computer Power Plus

Standards New Zealand

Standards New Zealand
 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news